Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.4613
-0.0117 (-2.47%)
Sep 9, 2026, 12:31 PM EDT - Market open
Ensysce Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.68 | 4.31 | 3.5 | 1.12 | 3.15 | 12.26 |
Cash & Short-Term Investments | 0.68 | 4.31 | 3.5 | 1.12 | 3.15 | 12.26 |
Cash Growth | -69.40% | 23.08% | 211.68% | -64.30% | -74.33% | 6215.06% |
Receivables | 0.42 | 0.42 | 0.12 | 0.1 | 0.28 | 0.44 |
Prepaid Expenses | 0.44 | 0.41 | 0.36 | 0.51 | 0.55 | 0.81 |
Other Current Assets | 1.31 | 2.11 | 1.36 | 0.55 | 1.33 | 2.15 |
Total Current Assets | 2.85 | 7.24 | 5.34 | 2.29 | 5.3 | 15.66 |
Property, Plant & Equipment | 0.11 | 0.12 | - | - | - | - |
Other Long-Term Assets | - | 0.09 | 0.25 | 0.42 | 0.59 | 0.75 |
Total Assets | 2.96 | 7.45 | 5.6 | 2.71 | 5.89 | 16.42 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.98 | 3.27 | 1.36 | 1.94 | 2.94 | 0.3 |
Accrued Expenses | 1.89 | 0.99 | 0.55 | 0.54 | 2.23 | 3.41 |
Short-Term Debt | 0.2 | 0.31 | 0.3 | 0.85 | 4.27 | - |
Current Portion of Long-Term Debt | - | - | - | - | - | 12.75 |
Current Portion of Leases | - | - | - | - | 0.03 | 0.02 |
Total Current Liabilities | 4.07 | 4.57 | 2.21 | 3.33 | 9.46 | 16.48 |
Long-Term Debt | - | - | - | - | 0.14 | 4.44 |
Other Long-Term Liabilities | - | - | 0.01 | 0.03 | 0.31 | 3.65 |
Total Liabilities | 4.07 | 4.57 | 2.22 | 3.36 | 9.91 | 24.58 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 145.06 | 142.93 | 133.25 | 121.23 | 107.22 | 77.97 |
Retained Earnings | -145.85 | -139.72 | -129.54 | -121.56 | -110.93 | -85.85 |
Total Common Equity | -0.78 | 3.21 | 3.71 | -0.32 | -3.71 | -7.88 |
Minority Interest | -0.33 | -0.33 | -0.33 | -0.33 | -0.32 | -0.28 |
Shareholders' Equity | -1.11 | 2.88 | 3.38 | -0.65 | -4.03 | -8.16 |
Total Liabilities & Equity | 2.96 | 7.45 | 5.6 | 2.71 | 5.89 | 16.42 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.2 | 0.31 | 0.3 | 0.85 | 4.43 | 17.21 |
Net Cash (Debt) | 0.48 | 4 | 3.2 | 0.27 | -1.29 | -4.95 |
Net Cash Growth | -73.15% | 25.10% | 1090.16% | - | - | - |
Net Cash Per Share | 0.07 | 1.57 | 4.59 | 1.78 | -107.24 | - |
Filing Date Shares Outstanding | 19.46 | 9.28 | 1.41 | 0.49 | 0.09 | 0.02 |
Total Common Shares Outstanding | 16.23 | 4.57 | 1.36 | 0.21 | 0.04 | - |
Working Capital | -1.22 | 2.67 | 3.14 | -1.04 | -4.17 | -0.82 |
Book Value Per Share | -0.05 | 0.70 | 2.74 | -1.54 | -104.24 | - |
Tangible Book Value | -0.78 | 3.21 | 3.71 | -0.32 | -3.71 | -7.88 |
Tangible Book Value Per Share | -0.05 | 0.70 | 2.74 | -1.54 | -104.24 | - |